Cardiol Therapeutics (CRDL) Equity Average (2021 - 2026)

Cardiol Therapeutics has reported Equity Average for 6 years, with the latest figure at $15.2 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 1.7% year-over-year to $15.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (up 1.7% YoY), and the FY2025 full-year result was $15.3 million, down 20.62% from the prior year.
• Equity Average for Q1 2026 stood at $15.2 million, up from $9.9 million in the prior quarter.
• The five-year high for Equity Average was $57.6 million in Q1 2022, with the low at $7.7 million in Q3 2025.
• Historically, Equity Average has averaged $25.2 million across 5 years, with a median of $17.8 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average soared 86.52% — and 2024, when it plunged 65.59%.
• Cardiol Therapeutics' Equity Average stood at $41.7 million in 2022, then slumped by 43.97% to $23.4 million in 2023, then plunged by 45.79% to $12.7 million in 2024, then decreased by 22.02% to $9.9 million in 2025, then jumped by 54.14% to $15.2 million in 2026.
• The last three Equity Average figures came in at $15.2 million (Q1 2026), $9.9 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.